Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript November 13, 2023 4:30 PM ET

Company Participants

Matt Murphy - Manager of IR

Chris Posner - CEO

Ryan Maynard - CFO

Joana Goncalves - Chief Medical Officer

Conference Call Participants

Joseph Stringer - Needham & Company

Sumant Kulkarni - Canaccord Genuity

David Amsellem - Piper Sandler

Annabel Samimy - Stifel

Oren Livnat - H.C. Wainwright

Operator

Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter Financial Results and Update conference call. All lines have been placed on mute to avoid any background noise. After the speaker remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that this call is being recorded.

I would now like to introduce Matt Murphy, Cara's Manager of Investor Relations. Mr. Murphy, you may begin your call.

Matt Murphy

Thank you, Operator, and good afternoon. After market closed today, Cara issued a news release announcing the company's financial and operating results for the third quarter of 2023. Copies of this news release and the associated SEC filing can be found in the investor section of our website at www.caratherapeutics.com.

Before we begin, let me remind you that during the course of this conference call, we will be making certain forward-looking statements about Cara and our programs based on management's current plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties. Actual results may differ materially due to various factors, and Cara undertakes no obligation to update or revise these statements publicly as a result of new information or future results or developments. Investors should read the risk factors set forth in Cara’s 10-K for the year ended December 31, 2022, and any subsequent reports filed with the SEC, including its Form 10-Q for the quarter ended September 30, 2023.

That said, I'd like to turn the call over to Chris Posner, Cara’s Chief Executive Officer. Chris?

Chris Posner

Thanks, Matt. Good afternoon, everyone, and thank you for joining our call. With me today are Ryan Maynard, our Chief Financial Officer; Dr. Joana Goncalves, our Chief Medical Officer; and Scott Terrillion, our General Counsel and Head of Government Affairs. Our strategy at Cara Therapeutics is to change the treatment of chronic pruritus with our innovative and differentiated asset difelikefalin.